Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-blind, Placebo Controlled, Randomised Study to Evaluate Antiviral Activity and Safety and Pharmacokinetics of Inhaled PC786 Against Respiratory Syncytial Virus (RSV) in Healthy Adult Subjects in a Virus Challenge Model

Trial Profile

A Single-blind, Placebo Controlled, Randomised Study to Evaluate Antiviral Activity and Safety and Pharmacokinetics of Inhaled PC786 Against Respiratory Syncytial Virus (RSV) in Healthy Adult Subjects in a Virus Challenge Model

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Feb 2019

At a glance

  • Drugs PC-786 (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Therapeutic Use
  • Sponsors Pulmocide
  • Most Recent Events

    • 15 May 2018 Status changed from active, no longer recruiting to completed.
    • 26 Mar 2018 Planned End Date changed from 1 Mar 2018 to 1 Apr 2018.
    • 26 Mar 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top